Abstract
Otsuka Pharmaceutical Company (OPC) is one of the largest healthcare companies
in Japan and one of the largest privately-held firms in the world. This report
provides a full review of the company's activities together with sales
forecasts for key products to 2010.
In fiscal 2005, (YE 31st March 2005) Otsuka reported consolidated
pharmaceutical sales of ¥434,100 million. Operating income totalled ¥65,865
million, an increase of 202.2% on the previous year, and net income totalled
¥37,025 million, an increase of 123.72% on the previous year.
Otsuka Pharmaceuticals has eight divisions in total including the
Pharmaceutical business division and the Consumer Products business division.
Expansion of the Pharmaceutical division has been concentrated on Asia and the
Middle East, with the establishment of new clinical R&D laboratories in China
and Thailand, and new drugs launches in South Korea and Vietnam.
R&D Pipeline Overview
- Acalas is for hypertension, angina pectoris and renoparenchymal
hypertension.
- Fijurin for the syndrome of inappropriate secretion of ADH.
- Last-F for the treatment of stomach, breast and lung cancers.
- Toborinone for acute and chronic heart failure, and circulation
insufficiency.
- Vitrase is indicated for diabetic retinopathy.
- Tolvaptan, a non-peptide vasopressin V2-receptor antagonist for the
treatment of congestive heart failure (CHF) and hyponatraemia.
View Cart
